Format

Send to

Choose Destination
Curr Neurol Neurosci Rep. 2016 Apr;16(4):39. doi: 10.1007/s11910-016-0640-y.

Practice Update: Review of Anticonvulsant Therapy.

Author information

1
Department of Neurology, Comprehensive Epilepsy Center, New York University, 223 E 34th Street, New York, NY, 10016, USA. dchong2@northwell.edu.
2
Department of Neurology, Comprehensive Epilepsy Center, New York University, 223 E 34th Street, New York, NY, 10016, USA.

Abstract

Since 2010, the Food and Drug Administration has approved the use of four new anti-epilepsy drugs (AEDs) for the treatment of epilepsy in the USA: clobazam (Onfi), ezogabine (Potiga), perampanel (Fycompa), and eslicarbazepine (Aptiom) as well as two extended release formulations, topiramate ER (Qudexy XR and Trokendi) and oxcarbazepine ER (Oxtellar). This not only provides practitioners ample choice to match medication profiles to their patients' preferences and co-morbidities better, but also challenges us to be proficient in the use of all. In addition to providing a brief overview of these new medications and of the current medical management of epilepsy, this review discusses new data regarding vitamin D and AED-related osteoporosis, pregnancy registries, suicidality, marijuana-related compounds for epilepsy, and the recently published guidelines on the approach and management of a first unprovoked seizure in adults and guidelines for when to stop AEDs.

KEYWORDS:

Adverse effects; Antiepileptic agents; Disease management; Drug therapy; Seizures; Selection

PMID:
26984292
DOI:
10.1007/s11910-016-0640-y
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center